Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 8:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,353 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Respiratory Virus Clear all
Recruiting Not applicable Interventional

Mind Body Intervention for Long COVID-19

NCT06045338
View directory record Official record
Conditions
Long COVID, Post-Acute Sequelae of COVID-19, COVID Long-Haul
Interventions
Mind Body Intervention #1
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Jun 10, 2026, 8:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Self-Administered Nasal Influenza Feasibility Study

NCT01933048
View directory record Official record
Conditions
Influenza
Interventions
FluMist
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 49 Years
Enrollment
1,077 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
San Diego, California • Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Jun 10, 2026, 8:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS

NCT04071158
View directory record Official record
Conditions
Respiratory Tract Infection
Interventions
RSV Vaccine, Tdap, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
713 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
16
States / cities
Stockbridge, Georgia • Honolulu, Hawaii • Wichita, Kansas + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2021 · Synced Jun 10, 2026, 8:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Prophylactic Antipyretics on Immune Responses and Fever After 2014-2015 and 2015-2016 Inactivated Influenza Vaccine

NCT02212990
View directory record Official record
Conditions
Fever
Interventions
Acetaminophen Arm, Placebo Arm, Ibuprofen Arm
Other
Lead sponsor
Duke University
Other
Eligibility
6 Months to 47 Months
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Jun 10, 2026, 8:57 PM EDT
Terminated Phase 3 Interventional Results available

COVID-19 3rd Dose Vaccine in Transplant Patients

NCT05047640
View directory record Official record
Conditions
Covid19
Interventions
BNT162b2 vaccine, JNJ-78436735 Vaccine
Biological
Lead sponsor
Giselle Guerra
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Jun 10, 2026, 8:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Prevention and Treatment of Patient Before, During, and After Covid-19 Infection

NCT05043324
View directory record Official record
Conditions
Covid19
Interventions
AntiCov-220, AntiCov-220 (placebo)
Drug
Lead sponsor
Nguyen Thi Trieu, MD
Individual
Eligibility
16 Years to 82 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Jun 10, 2026, 8:57 PM EDT
Terminated Phase 2 Interventional Results available

Treating COVID-19 With Hydroxychloroquine (TEACH)

NCT04369742
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine (HCQ), Placebo: Calcium citrate
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Jun 10, 2026, 8:57 PM EDT
Terminated Phase 2 Interventional

Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection

NCT04339426
View directory record Official record
Conditions
Covid19
Interventions
Atovaquone/Azithromycin
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years to 95 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Jun 10, 2026, 8:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations

NCT03617523
View directory record Official record
Conditions
Influenza
Interventions
Fluzone Quadrivalent vaccine, 2018-2019 formulation, Flublok Quadrivalent vaccine, 2018-2019 formulation, Fluzone High-Dose vaccine, 2018-2019 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
3
States / cities
Bardstown, Kentucky • Metairie, Louisiana • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Jun 10, 2026, 8:57 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

COVID-19 Breastfeeding Guideline for African-Americans

NCT04476940
View directory record Official record
Conditions
Covid19, Exclusive Breastfeeding
Interventions
COVID-19 Breastfeeding Support
Behavioral
Lead sponsor
Meharry Medical College
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Jun 10, 2026, 8:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults

NCT00488046
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2007 · Synced Jun 10, 2026, 8:57 PM EDT
Completed Phase 2 Interventional Results available

Smell in COVID-19 and Efficacy of Nasal Theophylline (SCENT 3)

NCT05947643
View directory record Official record
Conditions
COVID-19
Interventions
theophylline, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Jun 10, 2026, 8:57 PM EDT
Completed Phase 3 Interventional Results available

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza

NCT01231620
View directory record Official record
Conditions
Influenza, Human
Interventions
Zanamivir, Placebo to match zanamivir, Oseltamivir, Placebo to match oseltamivir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
16 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2018 · Synced Jun 10, 2026, 8:57 PM EDT
Completed Not applicable Interventional Results available

Behavioral Economics to Improve Flu Vaccination Using EHR Nudges

NCT06057727
View directory record Official record
Conditions
Behavior, Health, Flu, Flu Vaccination
Interventions
Pre-visit patient text messaging, Default pended order, Monthly peer comparison feedback, High risk bidirectional pre-visit text messaging
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years and older
Enrollment
80,039 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Jun 10, 2026, 8:57 PM EDT
Completed Not applicable Interventional

Testing the Use of Prompts to Increase Adolescent Immunization Rates

NCT01984125
View directory record Official record
Conditions
Vaccine Preventable Diseases, Meningococcal Disease, Human Papillomavirus, Pertussis, Influenza
Interventions
Point-of-Care Prompt
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
11 Years to 18 Years
Enrollment
7,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
22
States / cities
Little Rock, Arkansas • Wilmington, Delaware • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Jun 10, 2026, 8:57 PM EDT
Completed No phase listed Observational

HIV Infection and Tobacco Use Among Injection Drug Users in Baltimore, Maryland: A Pilot Study of Biomarkers

NCT00491335
View directory record Official record
Conditions
HIV Infections, AIDS, Lung Cancer, Tobacco Addiction, Drug Addiction
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
17 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 8:57 PM EDT
Completed Not applicable Interventional

Mindfulness in Post Acute Sequelae of SARS-CoV-2 Infection (PASC) Dysautonomia

NCT05566379
View directory record Official record
Conditions
Long COVID, Dysautonomia
Interventions
Mindfulness - Mindful Awareness Practices ( MAPs)
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 54 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Jun 10, 2026, 8:57 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT05267626
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Interventions
AU-007, Aldesleukin, Avelumab, Nivolumab
Drug
Lead sponsor
Aulos Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
11
States / cities
Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 8 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jun 10, 2026, 8:57 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy of Xlear vs. Placebo for Acute COVID-19 Infection

NCT04858620
View directory record Official record
Conditions
Covid19
Interventions
Xlear Nasal Spray, Placebo
Drug
Lead sponsor
Larkin Community Hospital
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Jun 10, 2026, 8:57 PM EDT
Not listed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831

NCT04480333
View directory record Official record
Conditions
Covid19, Corona Virus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia, Severe Acute Respiratory Syndrome of Upper Respiratory Tract, Neurodegeneration, Neuroinflammatory Response
Interventions
Drug: NA-831 - 0.10 mg/kg, Placebo- 0.10 mg/kg, Drug: NA-831 - 0.20 mg/kg, Placebo- 0.20 mg/kg, Drug: GS-5734 - 1.00 mg/kg, Placebo- 1.00 mg/kg, Drug: GS-5734 - 2.00 mg/kg, Placebo- 2.00 mg/kg, Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg), Placebo 0.10 mg + 1.00 mg/kg, Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg), Placebo 0.20 mg + 2.00 mg/kg
Drug · Combination Product
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Jun 10, 2026, 8:57 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Novel Point-of-Care Diagnostic Test for SARS-CoV-2 (COVID-19)

NCT04513990
View directory record Official record
Conditions
COVID-19 Infection
Interventions
Biospecimen Collection, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
257 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Jun 10, 2026, 8:57 PM EDT
Completed Phase 2 Interventional

Influenza Vaccination in Patients Receiving Antineoplastic Therapy for Non-Hodgkin's Lymphoma

NCT00307710
View directory record Official record
Conditions
Lymphoma
Interventions
Trivalent Baculovirus-expressed Influenza HA vaccine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Jun 10, 2026, 8:57 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Pharma-Pen (Formerly Innoject) Auto-injectory TIV

NCT00335855
View directory record Official record
Conditions
Influenza
Interventions
Auto-injector for IM/SC vaccine administration
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2006
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Jun 10, 2026, 8:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults

NCT00395174
View directory record Official record
Conditions
Influenza
Interventions
Influenza Vaccination
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
65 Years and older
Enrollment
870 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
7
States / cities
Baltimore, Maryland • Rochester, Minnesota • Shrewsbury, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2009 · Synced Jun 10, 2026, 8:57 PM EDT